Trials / Unknown
UnknownNCT06001606
Immunogenicity, Reactogenicity of Shingrix in SLE
Immunogenicity, Reactogenicity and Safety of 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus: a Randomized Clinical Trial.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the immunogenicity, reactogenicity and safety of 2 doses of the adjuvanted herpes zoster subunit vaccine (Shingrix) in patients with SLE in a randomized trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Shingrix | Shingrix vaccination |
| DRUG | Placebo | Placebo vaccination |
Timeline
- Start date
- 2023-05-08
- Primary completion
- 2025-04-24
- Completion
- 2025-04-24
- First posted
- 2023-08-21
- Last updated
- 2023-08-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06001606. Inclusion in this directory is not an endorsement.